nifekalant hydrochloride has been researched along with Atrial Fibrillation in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Hong, K; Hu, J; Li, J; Wu, Y; Xia, Z; Xiong, Q; Yu, J; Zhai, Z; Zhu, B | 1 |
| Di, C; Gao, P; Lin, W; Wang, Q; Wu, Y | 1 |
| Furue, M; Ichiki, T; Mitoma, C; Mukai, Y; Nakahara, T; Nishizaki, A; Uchi, H; Wada, M; Yasukouchi, Y | 1 |
| Bao, H; Chen, Q; Cheng, X; Fan, S; Hong, K; Hu, J; Huang, L; Huang, Q; Ju, Z; Li, J; Marian, AJ; Wu, Y; Xia, Z; Xiong, Q; You, C; Yu, J; Yuan, P; Zhu, B | 1 |
| Hirayama, A; Kofune, M; Kogawa, R; Mano, H; Nakai, T; Ohkubo, K; Okumura, Y; Sasaki, N; Sonoda, K; Watanabe, I | 1 |
| Enjoji, Y; Funatsu, A; Kambayashi, D; Kobayashi, T; Mizobuchi, M; Nakamura, S; Ono, T; Yamamoto, R | 1 |
| Hirayama, A; Kofune, M; Mano, H; Nagashima, K; Ohkubo, K; Okumura, Y; Sonoda, K; Watanabe, I | 1 |
| Kumagai, K; Toyama, H | 1 |
| Aoyagi, T; Fukushima, K; Kobayakawa, N; Otani, Y; Sawaki, D; Sekita, G; Takeuchi, H | 1 |
| Centurion, OA; Fukae, S; Isomoto, S; Komiya, N; Minami, T; Nakao, K; Yano, K | 1 |
| Kofune, T; Masaki, R; Okubo, K; Okumura, Y; Saito, S; Shindo, A; Watanabe, I | 1 |
| Hayashi, M; Kato, T; Kobayashi, Y; Morita, N; Sato, N; Takano, T; Tanaka, K; Yasutake, M | 1 |
| Sugi, K | 1 |
| Azegami, K; Hirao, K; Isobe, M; Miyagi, N; Nakamura, K; Ohba, K; Okishige, K; Shimabukuro, M; Uehara, H; Wakimoto, H | 1 |
| Hara, Y; Masuda, Y; Mori, K; Nakaya, H; Saito, T | 1 |
| Centurion, OA; Hayano, M; Hirata, T; Isomoto, S; Kaibara, M; Konoe, A; Yano, K | 1 |
| Fujiki, A; Hayashi, H; Inoue, H; Tani, M; Usui, M | 1 |
| Kanmatuse, K; Kojima, T; Kunimoto, S; Masaki, R; Nakai, T; Oshikawa, N; Ozawa, Y; Saito, S; Watanabe, H; Watanabe, I | 1 |
| Fuda, Y; Hagiwara, N; Haruta, S; Kasanuki, H; Matsuda, N; Shiga, T | 1 |
1 review(s) available for nifekalant hydrochloride and Atrial Fibrillation
| Article | Year |
|---|---|
[Strategy for cardiac arrhythmias in acute coronary syndrome].
Topics: Amiodarone; Angina, Unstable; Anti-Asthmatic Agents; Aprindine; Atrial Fibrillation; Bepridil; Electric Countershock; Humans; Myocardial Infarction; Potassium Channel Blockers; Pyrimidinones; Recurrence; Syndrome; Tachycardia, Ventricular; Ventricular Fibrillation | 2006 |
4 trial(s) available for nifekalant hydrochloride and Atrial Fibrillation
| Article | Year |
|---|---|
Comparison of the efficacy and safety of different doses of nifekalant in the instant cardioversion of persistent atrial fibrillation during radiofrequency ablation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electrocardiography; Female; Humans; Male; Middle Aged; Pyrimidinones; Radiofrequency Ablation | 2021 |
Usefulness of ablation of complex fractionated atrial electrograms using nifekalant in persistent atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality Therapy; Electrocardiography; Female; Humans; Male; Middle Aged; Prospective Studies; Pyrimidinones; Treatment Outcome | 2013 |
Enhancing electrical cardioversion and preventing immediate reinitiation of hemodynamically deleterious atrial fibrillation with class III drug pretreatment.
Topics: Aged; Aging; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Hemodynamics; Hospital Mortality; Humans; Male; Middle Aged; Premedication; Prognosis; Pyrimidinones; Secondary Prevention; Treatment Failure; Treatment Outcome | 2005 |
Clinical study of the acute effects of intravenous nifekalant on the defibrillation threshold in patients with persistent and paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric Countershock; Female; Humans; Male; Middle Aged; Pyrimidinones; Treatment Outcome | 2008 |
14 other study(ies) available for nifekalant hydrochloride and Atrial Fibrillation
| Article | Year |
|---|---|
Intraprocedural Conversion Efficacy of Intravenous Nifekalant Administration for Persistent Atrial Fibrillation after Pulmonary Vein Isolation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cryosurgery; Electric Countershock; Female; Heart Atria; Humans; Infusions, Intravenous; Intraoperative Care; Intraoperative Complications; Male; Middle Aged; Organ Size; Peripheral Nerve Injuries; Phrenic Nerve; Progression-Free Survival; Prospective Studies; Pulmonary Veins; Pyrimidinones; Recurrence; Tachycardia, Ventricular; Treatment Outcome | 2020 |
Crystallization granuloma by nifekalant hydrochloride infusion.
Topics: Aged; Atrial Fibrillation; Biopsy, Needle; Crystallization; Follow-Up Studies; Foot; Granuloma; Hand; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Pyrimidinones; Rare Diseases; Risk Assessment | 2018 |
Efficacy of Nifekalant in Patients With Wolff-Parkinson-White Syndrome and Atrial Fibrillation: Electrophysiological and Clinical Findings.
Topics: Accessory Atrioventricular Bundle; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Pyrimidinones; Tachycardia, Supraventricular; Ventricular Dysfunction, Left; Wolff-Parkinson-White Syndrome | 2019 |
Rate-dependent electrophysiologic effects of the class III antiarrhythmic drugs nifekalant, amiodarone, and ibutilide on the atrium in patients with persistent atrial fibrillation.
Topics: Action Potentials; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Female; Heart Atria; Heart Conduction System; Humans; Male; Middle Aged; Pyrimidinones; Sulfonamides | 2013 |
Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Body Surface Potential Mapping; Disopyramide; Humans; Male; Pyrimidinones; Syndrome; Tachycardia, Ventricular; Treatment Outcome; Young Adult | 2008 |
Pharmacologic atrial defibrillation by drug delivery into the temporarily occluded coronary sinus. A canine study.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Balloon Occlusion; Cardiac Pacing, Artificial; Chronic Disease; Coronary Sinus; Dogs; Drug Delivery Systems; Injections, Intravenous; Lidocaine; Pyrimidinones; Treatment Outcome | 2012 |
Pretreatments with a novel pure potassium channel blocker, Nifekalant, were effective in the electrical atrial defibrillation: a report of two cases.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Defibrillators, Implantable; Electric Countershock; Female; Humans; Male; Potassium Channel Blockers; Pyrimidinones | 2002 |
Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation; Atrial Function; Bundle of His; Coronary Vessels; Electrocardiography; Electrophysiology; Female; Heart Ventricles; Humans; Infusions, Intravenous; Linear Models; Male; Matched-Pair Analysis; Middle Aged; Pyrimidinones; Refractory Period, Electrophysiological; Time Factors | 2004 |
Effect of IKr blocker nifekalant on atrial action potential duration after successful internal cardioversion of chronic atrial fibrillation.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershock; Female; Heart Atria; Heart Rate; Humans; Male; Middle Aged; Pyrimidinones; Refractory Period, Electrophysiological | 2005 |
Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms.
Topics: Acetylcholine; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function, Left; Cells, Cultured; Guinea Pigs; Heart Atria; In Vitro Techniques; Myocardial Contraction; Patch-Clamp Techniques; Piperidines; Potassium Channels; Pyridines; Pyrimidinones; Receptors, Muscarinic; Sotalol | 1995 |
Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Blood Pressure; Bundle of His; Electrocardiography; Electrophysiology; Female; Heart Atria; Heart Rate; Heart Ventricles; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Pyrimidinones; Refractory Period, Electrophysiological; Sinoatrial Node; Tachycardia | 1995 |
Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Dogs; Electric Stimulation; Female; Lidocaine; Male; Pyrimidinones; Vagus Nerve | 1998 |
Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium.
Topics: Action Potentials; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Cohort Studies; Drug Evaluation; Electrophysiologic Techniques, Cardiac; Flecainide; Heart Atria; Humans; Middle Aged; Pyrimidinones; Sotalol | 2001 |
Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; Heart Failure; Humans; Infusions, Intravenous; Male; Middle Aged; Pyrimidinones; Tachycardia | 2002 |